595k/year That's a hefty price for the drug!
"According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 8.91x, though it currently operates at a loss. The newly approved drug is priced at $595,000 per year, which aligns with the anticipated cost for treatments targeting ultra-rare diseases. This development signifies Ionis Pharmaceuticals' first solo commercial drug launch...
The larger indication for severe hypertriglyceridemia (sHTG) is seen as the primary value driver for olezarsen, with analyst price targets ranging from $37 to $78. Results from pivotal studies for this indication are expected in the second half of 2025."
https://www.investing.com/news/analyst-ratings/ionis-shares-hold-as-piper-sandler-stays-positive-on-fda-nod-93CH-3787182